^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Source:
Title:

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Excerpt:
...1 pt developed acquired resistance to vemurafenib with KRAS mutation….
DOI:
https://doi.org/10.1182/blood-2018-99-119949